EMG
KPTI icon

Ellington Management Group’s Karyopharm Therapeutics KPTI Stock Holding History

Ellington Management Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,080
Closed -$109K – 662
2016
Q2 		$109K Buy
+1,080
New +$140K 0.15% 210

Other funds holding KPTI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ellington Management Group's KPTI Position: Q3 2016 in Review

Ellington Management Group sold out of Karyopharm Therapeutics (KPTI) in Q3 2016, closing a stake of 1,080 shares — an estimated $109K sold.

Ellington Management Group first reported a position in KPTI in Q2 2016 and held it in 1 quarter. The position peaked at $109K in Q2 2016. 79 funds tracked by Wall St. Rank hold KPTI as of Q3 2016.

  • Ellington Management Group reported no remaining Karyopharm Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Ellington Management Group sold 1,080 Karyopharm Therapeutics shares in Q3 2016, an estimated $109K.
  • Ellington Management Group first reported a position in Karyopharm Therapeutics in Q2 2016 and held it in 1 quarter.
  • Ellington Management Group's Karyopharm Therapeutics position peaked at $109K in Q2 2016.
  • 79 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2016.

Based on Ellington Management Group's 13F filing for Q3 2016, filed 14 Nov 2016.